Nafarelin

Summary Synopsis Nafarelin, a synthetic agonist of gonadotrophin-releasing hormone (GnRH) [luteinising hormone-releasing hormone (LH-RH); gonadorelin] appears likely to join the other GnRH analogues currently used in a range of conditions reliant on gonadotrophins or sex hormones. With repeated administration, the pituitary becomes desensitised, and gonadotrophin release, and therefore sex hormone synthesis, are inhibited. Nafarelin has proved to be comparable to danazol in the management of women with endometriosis, with fewer potentially harmful adverse effects. Nafarelin has also been used effectively in in vitro fertilisation programmes, and in hirsute women and those with uterine leiomyoma, particularly to induce preoperative fibroid shrinkage. The drug shrinks hypertrophic tissue in men with benign prostatic hyperplasia, although treatment would need to be maintained indefinitely and therefore should probably be reserved for those unsuitable for prostatectomy. Preliminary data suggest that nafarelin is equivalent to diethylstilbestrol (stilboestrol) in terms of disease-free survival in men with prostate cancer. As a reliable method of contraception, nafarelin gives unpredictable results in men and the promising results in women may be offset by hypoestrogenic side effects. Nafarelin may join other GnRH agonists which are now routinely used in the management of children with central or combined precocious puberty. Nafarelin is readily and rapidly absorbed following intranasal delivery, and is protected to some extent from enzymatic degradation. The resultant relatively long elimination half-life allows once-or twice-daily administration. Estrogen depletion accounts for the most common side effects associated with nafarelin, including hot flushes and vaginal dryness, which are mild and tolerable in most patients. Reversible resorption of trabecular bone can occur during nafarelin therapy, perhaps necessitating cyclical treatment to enable bone mass to recover. Nafarelin, therefore, looks likely to find a role in the treatment of women with endometriosis, and results achieved in other conditions dependent on the pituitary-gonadal axis are promising. Pharmacodynamic Properties Nafarelin is a synthetic analogue of GnRH and is about 200 times more potent than the endogenous peptide. It stimulates the release of the gonadotrophins luteinising hormone (LH) and follicle stimulating hormone (FSH) from the anterior pituitary, but this effect gradually wanes with multiple doses as the pituitary becomes desensitised, possibly from down-regulation of receptors. Single intranasal or subcutaneous doses of nafarelin elevate serum LH and FSH levels in both sexes. The magnitude and rate of gonadotrophin release are greatest in women during the late follicular and luteal phases of the menstrual cycle. After 2 or 3 days of daily nafarelin administration, the pituitary becomes refractory, and LH and FSH release is inhibited within 10 days. Intermittent intramuscular administration of testosterone enanthate 200mg enhances gonadotrophin suppression in healthy men. Although variable between individuals, pituitary desensitisation is proportional to nafarelin dosage. Like other GnRH agonists, nafarelin also appears to reduce the biological activity of LH. In men, serum testosterone levels initially increase after subcutaneous administration of nafarelin 10 to 200μg, and then gradually decline to below baseline after 10 days. Spermatogenesis is suppressed by up to 92% during treatment with nafarelin 200 or 400 μg/day subcutaneously plus concomitant fortnightly testosterone enanthate 200mg intramuscularly, although azoospermia is rare and unpredictable. Sperm counts normalise within 16 weeks of stopping nafarelin. In women, single intranasal doses of 125 or 500μg, and 1, 5 or 100μg subcutaneously, increase mean serum estradiol levels by 2 to 4 times in a dose-proportional manner. The greatest increases occur when nafarelin is given during the early follicular phase of the cycle. Peak estradiol release occurs after 2 weeks’ administration, and then steadily decreases to pretreatment levels or lower. Despite variable responses, mean progesterone levels increase initially and then fall to pretreatment values after 10 days of daily nafarelin administration during the luteal phase. Levels of progesterone indicative of ovulation have been detected in fewer than 18% of cycles during intranasal delivery of nafarelin acetate 125 or 250 μg/day for 3 to 6 months. With a twice-daily dosage of nafarelin 500μg, progesterone release and ovarian testosterone synthesis appear to be completely inhibited. Single doses of nafarelin 1, 5, 20 or 100μg given subcutaneously during the early follicular phase lengthen the mean menstrual cycle duration and postpone ovulation. Amenorrhoea and oligomenorrhoea are common during 3 to 6 months’ intranasal administration of nafarelin acetate 125 or 250 μg/day, with ovulatory menses re-established between 28 and 48 days after discontinuing the drug. To summarise, single doses of nafarelin stimulate the release of LH and FSH, which provokes sex steroid production. With repeated administration, the pituitary becomes desensitised and gonadotrophin release is inhibited. The biological activity of LH may also be altered. Consequently, follicle maturation, ovulation and luteinisation are usually prevented in women, resulting in reduced estrogen and progesterone synthesis, and in men testosterone production and spermatogenesis are inhibited. Pharmacokinetic Properties Nafarelin is a decapeptide and therefore susceptible to gastrointestinal peptidase degradation, making it unsuitable for oral administration. Mean peak nafarelin plasma concentrations (Cmax), achieved within 5 to 60 minutes, were 13.6 μg/L after a single subcutaneous dose of nafarelin 400μg, and 0.1, 0.35 and 1.59 μg/L following intranasal doses of 84, 206 and 336μg, respectively, in healthy men and women. Intranasal absorption is enhanced by using more concentrated solutions of nafarelin and by including sodium glycocholate in the formulation. The mean bioavailability of nafarelin following intranasal administration is about 4 to 21%. Nafarelin is rapidly and extensively distributed to extravascular tissue in animals, despite about 80% being bound to plasma proteins in vitro, principally to albumin. Six metabolites, together with the parent compound, accounted for 36% of the total dose and 85% of urinary radioactivity after a subcutaneous dose of 14C-nafarelin 216μg in 3 healthy men. The major metabolites, each representing about 20% of the total urinary activity, were the (5–10) hexapeptide amide and naphthylalanine. About half of the total radioactivity was recovered in the urine and 19 to 44% in the faeces over 7 days. The elimination half-life (t½) is about 2 or 3 hours following intranasal delivery of nafarelin and 4 or 5 hours after subcutaneous administration, longer than the t½ of 30 minutes for native GnRH as a result of nafarelin being more resistant to peptidase degradation. A plasma concentration as low as 50 ng/L is needed for nafarelin to elicit a response at the pituitary in some individuals. Peak gonadotrophin levels in response to single doses of nafarelin lagged about 2 to 3 hours behind the Cmax of the drug. Therapeutic Use Nafarelin has been used successfully in both sexes in a range of conditions dependent on the pituitary-gonadal axis. In open small-scale trials, nafarelin 20 to 1000 μg/day administered subcutaneously or intranasally reduced the symptoms and signs of endometriosis within 3 months. More importantly, 2 well-designed comparative studies each involving around 200 patients revealed reductions in American Fertility Society severity scores of 43 to 49%, and similar improvements in symptom relief and ectopic tissue eradication in women receiving nafarelin 200 or 400μg twice daily intranasally, or danazol 400mg twice daily or 200mg 3 times daily orally for 6 months. Over 70% of women in 1 study were symptom-free or had only mild symptoms 6 months after stopping either drug. In 10 women with uterine leiomyoma (fibroids), intranasal nafarelin 800 μg/day reduced uterine volume by 57% (mean) after 6 months, corresponding to a decrease in estradiol levels. Shrinkage of fibroids was variable, but nevertheless facilitated surgical excision. Since myomas increased in size again once nafarelin was stopped and ovarian estrogen synthesis restored, myomectomy following preoperative shrinkage with nafarelin may represent the optimum use for the drug in this setting. Inhibition of ovarian testosterone production by intranasal administration of nafarelin 500μg twice daily for 6 months resulted in a clinical improvement in 6 hirsute women, including 4 with polycystic ovary syndrome. The effects of the lower dose of 200μg twice daily on ovarian volume and number of follicles in another 11 patients with polycystic ovary syndrome were inconsistent, and only modest improvements were achieved in the hirsutism of 7 of the women. Nafarelin 400 μg/day intranasally successfully suppressed ovarian function in 53 women undergoing in vitro fertilisation. Subsequent stimulation of follicular development with menotropins [human menopausal gonadotrophin (HMG)] led to adequate follicle numbers, and 33 patients progressed to embryo transfer; 10 pregnancies resulted. In 9 men with benign prostatic hyperplasia, daily subcutaneous injections of nafarelin acetate 400μg suppressed circulating testosterone below castrate levels (about 1 nmol/L) and decreased mean prostate size by 25% after 4 months. Obstructive and, to a lesser extent, irritative symptoms were relieved, but urinary flow rate improved to a clinically significant degree in only 3 men. Virtually all the hypertrophic tissue returned when nafarelin was stopped. Thus, continued treatment would be necessary to maintain remission, and should be reserved for those patients unsuitable for prostatectomy. Although other GnRH agonists are now accepted treatment for men with stage D2 prostatic carcinoma, data regarding the use of nafarelin in such patients are limited. Seven of 9 men treated with daily subcutaneous injections of nafarelin 400μg responded according to National Prostatic Cancer Project criteria, with a median time to disease progression of about 16 months and a median survival time of over 2 years. In a comparative study, castrate testosterone levels were achieved in 60 recipients of nafarelin acetate 300μg intranasally twice daily and in 65 men receiving diethylstilbestrol 1mg orally 3 times daily, with similar disease-free survival rates of 84% and 70%, respectively, after 6 months’ follow-up. The contraceptive potential of 3 to 6 months of intranasal administration of nafarelin acetate 125 or 250μg once daily has been evaluated in groups of 8 to 25 healthy women. Overall, pregnancy was prevented during a total of 281 months when nafarelin was the only contraceptive method used by 77 women. Presumed ovulation was inhibited in over 81% of cycles during administration of the lower dose, and in at least 97% with the higher dose. Endometrial biopsy specimens generally revealed atrophic or weakly proliferative tissue. Bleeding patterns were disrupted and unpredictable during nafarelin treatment, with amenorrhoea present in 40 to 60% of women receiving 125 μg/day and in 10 to 87% with twice this dosage. Ovulatory menses were usually re-established 30 to 45 days after discontinuing nafarelin. Nafarelin 400, 800, 1200 or 1600 μg/day, given as a single daily intranasal dose or in 3 divided doses, slowed the linear growth rate of small groups of children with central or combined precocious puberty by 30 to 50%. Suppression of secondary sexual characteristics was inconsistent. Adverse Effects The reduction in circulating estrogens accounts for the most frequently reported adverse effects of nafarelin. Hot flushes, usually mild and tolerable, were experienced by 38 to 65% of women receiving nafarelin acetate 250 μg/day intranasally and by over 90% with higher doses. Women also reported reduced libido and vaginal dryness. In 10 men with benign prostatic hyperplasia receiving nafarelin 400 μg/day subcutaneously, hot flushes and impotence were universal. These troublesome, but not dangerous, unwanted effects occurred more frequently with nafarelin than with danazol in women receiving treatment for endometriosis. However, nafarelin was associated with a lower incidence of weight gain, oedema, myalgia and elevated serum liver enzymes than danazol and, unlike danazol, was not associated with undesirable changes in serum lipids. Trabecular bone mineral density decreased by 6 to 11% over a 6-month period of therapy with nafarelin 400 or 600 μg/day, caused by increased bone resorption associated with lower estrogen levels. Most of this lost bone mass was recuperated on nafarelin withdrawal, and appeared to be minimised by concomitant hormone replacement therapy. Nasal irritation has occasionally been reported following intranasal administration of nafarelin, as has headache and emotional lability. Disease ‘flare’ associated with the short term stimulation of gonadotrophin and sex hormone release at the beginning of therapy does not appear to be common. Dosage and Administration Since nafarelin is inactive if given orally, it is routinely administered intranasally or occasionally subcutaneously. Twice daily intranasal application of 200 to 500μg has been effective in women with endometriosis, leiomyoma or hirsutism, and in men with prostatic carcinoma. Subcutaneous injections of 400 μg/day have also been used in prostate cancer patients and in men with benign prostatic hypertrophy. In female contraception, intranasal administration of nafarelin acetate 250 μg/day prevented ovulation almost completely, whereas a less predictable response was obtained with 125μg daily. Intranasal dosages ranging from 400 to 1600μg — but usually 25 μg/kg given as a single daily dose or in 3 divided doses — have been employed with generally favourable results in children with central or combined precocious puberty. Similar content being viewed by others References Andreyko JL, Blumenfeld Z, Marshall LA, Monroe SE, Hricak H, et al. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment of magnetic resonance imaging. American Journal of Obstetrics and Gynecology 158: 903–910, 1988 Andreyko JL, Monroe SE, Jaffe RB. Treatment of hirsutism with a gonadrotropin-releasing hormone agonist (nafarelin). Journal of Clinical Endocrinology and Metabolism 63: 854–859, 1986 Barbieri RL. New therapy for endometriosis. New England Journal of Medicine 318: 512–514, 1988 Barbieri RL. Comparison of the pharmacology of nafarelin and danazol. American Journal of Obstetrics and Gynecology 162: 581–585, 1990a Barbieri RL. Gonadotropin-releasing hormone agonists and estrogen-progestogen replacement therapy. American Journal of Obstetrics and Gynecology 162: 593–595, 1990b Barbieri RL. Endometriosis 1990: current treatment approaches. Drugs 39: 502–510, 1990c Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 202: 631–633, 1978 Bhasin S, Heber D, Steiner B, Peterson M, Blaisch B, et al. Hormonal effects of GnRH agonist in the human male. II. Testosterone enhances gonadotrophin suppression induced by GnRH agonist. Clinical Endocrinology 20: 119–128, 1984 Bhasin S, Heber D, Steiner BS, Handelsman DJ, Swerdloff RS. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen. Journal of Clinical Endocrinology and Metabolism 60: 998–1003, 1985a Bhasin S, Steiner B, Swerdloff R. Does constant infusion of gonadotropin-releasing hormone agonist lead to greater suppression of gonadal function in man than its intermittent administration? Fertility and Sterility 44: 96–101, 1985b Brenner PF, Shoupe D, Mishell Jr DR. Ovulation inhibition with nafarelin acetate nasal administration for six months. Contraception 32: 531–551, 1985 Brogden RN, Buckley M-T, Ward A. Buserelin: a review of its pharmacodynamic and pharmacokinetic properties and clinical profile. Drugs 39: 399–437, 1990 Brzyski RG, Comite F. Nafarelin, an intranasal GnRH analog, for infertility association with endometriosis. Abstract. American Fertility Society Annual Meeting, September 28-October 2, 1987 Brzyski RG, Comite FC. Effect of nafarelin dose on rate and magnitude of suppression of precocious pubertal development. Abstract. Endocrine Society Annual Meeting, New Orleans, June 8–11, 1988 Burry KA, Patton PE, Illingworth DR. Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol. American Journal of Obstetrics and Gynecology 160: 1454–1461, 1989 Cann CE, Henzl M, Burry K, Andreyko J, Hanson F, et al. Reversible bone loss is produced by the GnRH agonist nafarelin. In Cohn et al. (Eds) Calcium regulation and bone metabolism: basic and clinical aspects, Vol. 9, pp. 123–127, Elsevier Science Publishers, Amsterdam, 1987 Chan RL, Chaplin MD. Plasma binding of LHRH and nafarelin acetate, a highly potent LHRH agonist. Biochemical and Biophysical Research Communications 127: 673–679, 1985a Chan RL, Chaplin MD. Identification of major urinary metabolites of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in the rhesus monkey. Drug Metabolism and Disposition 13: 566–571, 1985b Chan RL, Henzl MR, LePage ME, LaFargue J, Nerenberg CA, et al. Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. Clinical Pharmacology and Therapeutics 44: 275–282, 1988 Chiang R-S, Barnes RB, Shoupe D, Lobo RA. Dose-related changes in LH bioactivity with intranasal GnRH agonist administration. Contraception 32: 347–357, 1985 Chu NI, Chan RL, Hama KM, Chaplin MD. Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys. Drug Metabolism and Disposition 13: 560–565, 1985 Claesson B, Bergquist C. Clinical experience treating endometriosis with nafarelin. Journal of Reproductive Medicine 34 (Suppl.): 1025–1028, 1989 Decensi AU, Guarneri D, Boccardo F. Correspondence. New England Journal of Medicine 318: 581, 1988 Eisenberger M, Silva H, Kalash S, Henzl M, Hoffman P. Effective long term androgenic suppression and clinical benefits with nafarelin acetate: a new intranasal LHRH analog for prostatic cancer (CA). Abstract. American Society of Clinical Oncologists Annual Meeting, May 4–6, 1986 Evans RM, Doelle GC, Lindner J, Bradley V, Rabin D. A luteinizing hormone-releasing hormone agonist decreases biological activity and modifies Chromatographic behaviour of luteinizing hormone in man. Journal of Clinical Investigation 73: 262–266, 1984 Filicori M, Flamigni C. GnRH agonists and antagonists: current clinical status. Drugs 35: 63–82, 1988 Griffin III JE, Wilson J.D. Disorders of the testis. In Braunwald et al. (Eds) Harrison’s principles of internal medicine, 11th ed., p. 1808, McGraw Hill, New York, 1987 Gross KM, Bremner WJ. Treatment of stage D2 prostatic carcinoma with combined gonadal and adrenal suppression in a 60-year-old man. American Journal of Medicine 83: 359–361, 1987 Gudmundsson JA, Ljunghall S, Bergquist C, Wide L, Nillius SJ. Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition. Journal of Clinical Endocrinology and Metabolism 65: 159–163, 1987b Gudmundsson JA, Lundkvist O, Bergquist C, Lindgren A, Nillius SJ. Endometrial morphology after 6 months of continuous treatment with a new gonadotropin-releasing hormone superagonist for contraception. Fertility and Sterility 48: 52–56, 1987a Gudmundsson JA, Nillius SJ, Bergquist C. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH. Contraception 30: 107–114, 1984 Gudmundsson JA, Nillius SJ, Bergquist C. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months’ clinical results. Fertility and Sterility 45: 617–623, 1986 Halme J, Hammond MG, Hulka JF, Raj SG, Talbert LM. Retrograde menstruation in healthy women and in patients with endometriosis. Obstetrics and Gynecology 64: 151–154, 1984 Heber D, Bhasin S, Steiner B, Swerdloff RS. The stimulatory and down-regulatory effects of a gonadotropin-releasing hormone agonist in man. Journal of Clinical Endocrinology and Metabolism 58: 1084–1088, 1984 Henzl MR. Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine 34 (Suppl.): 1021–1024, 1989 Henzl MR, Chaplin MD, Nerenberg C, Monroe SE, Kushinsky S. Correlation between blood levels of 6-D-3 (2-naphthyl-alanine)-GnRH and LH stimulation after subcutaneous and nasal administrations. Abstract. Society for Gynecologic Investigation Annual Meeting, Washington, DC, March 1983 Henzl MR, Corson SL, Moghissi K, Buttram VC, Bergquist C, et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial. New England Journal of Medicine 318: 485–489, 1988 Henzl MR, Monroe SE. Treatment of endometriosis by nasal administration of nafarelin. In Vickery and Nestor (Eds) LHRH and its analogs: contraceptive and therapeutic applications, Part II, pp. 337–347, MTP Press, Lancaster, 1987 Hoffman PG, Henzl MR, Chaplin MD, Nerenberg CA. Clinical development of nafarelin acetate. Phase I and phase II studies. Journal of Andrology 8: S17–S22, 1987 Jacobson JB. Effects of nafarelin on bone density. American Journal of Obstetrics and Gynecology 162: 591–592, 1990 Jeffcoate SL, Greenwood RH, Holland DT. Blood and urine clearance of luteinizing hormone releasing hormone in man measured by radioimmunoassay. Journal of Endocrinology 60: 305–314, 1974 Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, et al. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. Journal of Clinical Endocrinology and Metabolism 67: 701–706, 1988 Kent JS, Sanders LM, Tice TR, Lewis DH. Microencapsulation of the peptide nafarelin acetate for controlled release. In Zatuchni (Ed) Long acting contraceptive delivery systems, pp. 169–179, Harper and Row, Philadelphia, 1984 Koehler B, Koehler M, Osuch-Jaczewska R. Intranasal LH-RH analogue treatment of precocious puberty. Experimental and Clinical Endocrinology 92: 252–256, 1988 Labrie F, Dupont A, Bélanger A, St-Arnaud R, Giguère M, et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrine Reviews 7: 67–74, 1986 Lin T-H, LePage ME, Henzl M, Kirkland JL. Intranasal nafarelin: an LH-RH analogue treatment of gonadotropin-dependent precocious puberty. Journal of Pediatrics 109: 954–958, 1988 Lyles R, Buttram VC, Goldzieher JW, Young RL. The use of a gonadotropin releasing hormone agonist (GnRH-a) in the treatment of endometriosis. Abstract. American Fertility Society Annual Meeting, September 27-October 2, 1985 Martin MC. Gonadotropin releasing hormone agonists and the induction or augmentation of ovulation. Journal of Reproductive Medicine 34 (Suppl): 1034–1038, 1989 McRae GI, Roberts BB, Worden AC, Schriock E, Lewis V, et al. Ablation of folliculogenesis in women by a single dose of gonadotropin-releasing hormone agonist: significance of time in cycle. Fertility and Sterility 43: 361–368, 1985 Monroe SE, Blumenfeld Z, Andreyko JL, Schriock E, Henzl MR, et al. Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin). Journal of Clinical Endocrinology and Metabolism 63: 1334–1341, 1986 Monroe SE, Henzl MR, Martin MC, Schriock E, Lewis V, et al. Ablation of folliculogenesis in women by a single dose of gonadotropin-releasing hormone agonist: significance of time in cycle. Fertility and Sterility 43: 361–368, 1985 Nerenberg C, Foreman J, Chu N, Chaplin MD, Kushinsky S. Radioimmunoassay of nafarelin ([6-(3-(2-naphthyl)-D-alanine)]-luteinizing hormone releasing hormone) in plasma or serum. Analytical Biochemistry 141: 10–16, 1984 Nestor Jr JJ, Ho TL, Simpson RA, Homer BL, Jones GH, et al. Synthesis and biological activity of some very hydrophobic superagonist analogues of luteinizing hormone-releasing hormone. Journal of Medicinal Chemistry 25: 795–801, 1982 Nillius SJ. Gonadotropin releasing hormone analogs for female contraception by inhibition of ovulation. Journal of Steroid Biochemistry 23: 849–854, 1985 Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. New England Journal of Medicine 317: 599–604, 1987 Rolland R, van der Heijden PFM. Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics and Gynecology 162: 586–588, 1990 Rolland R, et al. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. 2nd International Symposium on Endometriosis, Houston, May 1–3, 1989 Sagalowsky AI, Wilson JD. Hyperplasia and carcinoma of the prostate. In Braunwald et al. (Eds) Harrison’s principles of internal medicine, 11th ed., p. 1582, McGraw Hill, New York, 1987 Sanders LM, Kent JS, McRae GI, Vickery BH, Tice TR, et al. Controlled release of a luteinizing hormone-releasing hormone analogue from poly(d,l-lactide-co-glycolide) microspheres. Journal of Pharmaceutical Sciences 73: 1294–1297, 1984a Sanders LM, McRae GI, Vitale KM, Vickery BH, Kent JS. An injectable biodegradable controlled release delivery system for nafarelin acetate. In Labrie et al. (Eds) LHRH and its analogues, Elsevier Science Publishers, Amsterdam, 1984b Schriock E, Monroe SE, Henzl M, Jaffe RB. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin). Fertility and Sterility 44: 583–588, 1985a Schriock ED, Monroe SE, Martin MC, Henzl MR, Jaffe RB. Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin). Fertility and Sterility 43: 844–850, 1985b Shaw RW. Use of nafarelin to investigate the pathophysiology of the polycystic ovary syndrome. Journal of Reproductive Medicine 34 (Suppl.): 1039–1043, 1989 Shaw RW. Nafarelin in the treatment of pelvic pain caused by endometriosis. American Journal of Obstetrics and Gynecology 162: 574–576, 1990 Stephure DK, Silverman BL, Conte FA, Rosenthal SM, Kaplan SL, et al. Treatment of true precocious puberty (TPP) with an intranasal (IN) luteinizing hormone releasing factor (LRF) agonist (A). Abstract. Society for Pediatric Research, Baltimore, June 1985 Stetler-Stevenson MA, Yang DC, Lipkowski A, McCartney L, Peterson D, et al. An approach to the elucidation of metabolic breakdown products of the luteinizing hormone-releasing hormone. Journal of Medicinal Chemistry 24: 688–692, 1981 Swerdloff RS, Steiner BS, Bhasin S. Gonadotropin releasing hormone (GnRH) agonists in male contraception. Medical Biology 63: 218–224, 1985 Välimäki M, Nilsson CG, Roine R, Ylikorkala O. Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis. Journal of Clinical Endocrinology and Metabolism 69: 1097–1103, 1989 Vickery BH. Female contraceptive potential of ‘super’ agonists of LHRH as assessed in infrahuman primates. In Zatuchni et al. (Eds) LHRH peptides as female and male contraceptives, pp. 109–125, Harper and Row, Philadelphia, 1981a Vickery BH. Physiology and antifertility effects of LHRH and agonistic analogs in male animals. In Zatuchni et al. (Eds) LHRH peptides as female and male contraceptives, pp. 275–290, Harper and Row, Philadelphia, 1981b Vickery BH, Anik S, Chaplin M, Henzl M. Intranasal administration of nafarelin acetate contraception and therapeutic applications. In Chien (Ed.) Transnasal systemic medications, pp. 201–215, Elsevier Science Publishers, Amsterdam, 1985a Vickery BH, McRae GI. Male contraceptive potential of nafarelin acetate assessed in the dog. In Vickery (Ed) LHRH and its analogs: contraceptive and therapeutic applications, pp. 61–75, MTP Press, Lancaster, 1984 Vickery BH, McRae GI, Briones WV, Roberts BB, Worden AC, et al. Dose-response studies on male reproductive parameters in dogs with nafarelin acetate, a potent LHRH agonist. Journal of Andrology 6: 53–60, 1985b Williams IA, Shaw RW, Burford G. An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist — nafarelin. Clinical Endocrinology 31: 345–353, 1989 Author information Authors and Affiliations Additional information Various sections of the manuscript reviewed by: R.L. Barbieri, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, Massachusetts, USA; D.H. Barlow, Nuffield Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Oxford, England; M. Filicori, University of Bologna, Centro di Cronobiologia della Reproduzione, Bologna, Italy; I.M. Holdaway, Section of Endocrinology, Auckland Hospital, Auckland, New Zealand; J. W. Goldzieher, Department of Obstetrics and Gynecology, Baylor College of Medicine, Texas Medical Center, Houston, Texas, USA; P.J. Nicholls, Welsh School of Pharmacy, University of Wales College of Cardiff, Cardiff, Wales; R.S. Swerdloff, Division of Endocrinology, University of California, Los Angeles School of Medicine, Torrance, California, USA. Rights and permissions About this article Cite this article Chrisp, P., Goa, K.L. Nafarelin. Drugs 39, 523–551 (1990). https://doi.org/10.2165/00003495-199039040-00005 Published: Issue date: DOI: https://doi.org/10.2165/00003495-199039040-00005